LUNG CANCER

Empowering People to be Ambassadors of their Own Health Since 1997.

Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, July 2014

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation.Liu CC1, Lin JH, Hsu TW, Su K, Li AF, Hsu HS, Hung SC. Int J Cancer. 2014 Jun 20. doi: 10.1002/ijc.29033. [Epub ahead of print]

GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.Tessema M1, Yingling CM, Snider AM, et al. J Thorac Oncol. 2014 Jun;9(6):784-93. doi: 10.1097/JTO.0000000000000165.

Synergistic effects of eukaryotic coexpression plasmid carrying LKB1 and FUS1 genes on lung cancer in vitro and in vivo.Li L, Yu C, Ren J, et al. J Cancer Res Clin Oncol. 2014 Jun;140(6):895-907.

Decreased Expression of miR-216a Contributes to Non-small Cell Lung Cancer Progression. Wang RT1, Xu M2, Song ZG3, Xu CX4, Jin H5. Clin Cancer Res. 2014 Jun 23. pii: clincanres.0517.2014. [Epub ahead of print]

Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Wilkerson MD1, Cabanski CR2, Sun W3, et al. Nucleic Acids Res. 2014 Jun 26. pii: gku489. [Epub ahead of print]

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes expanding the repertoire of potential immunotherapeutic targets.Taguchi A1, Taylor AD2, Rodriguez J3, et al. Cancer Res. 2014 Jun 26. pii: canres.3725.2013. [Epub ahead of print]

Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.Shao C1, Sullivan JP2, Girard L3, et al. Clin Cancer Res. 2014 Jun 6. pii: clincanres.3292.2013. [Epub ahead of print]

Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer.Liu J, Liu C, Qiu L, Li J, Zhang P, Sun Y. Diagn Pathol. 2014 Jun 27;9(1):128. [Epub ahead of print]

Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal-/- mice.Zhao T1, Du H2, Ding X1, Walls K1, Yan C3. Oncogene. 2014 Jun 2;0. doi: 10.1038/onc.2014.143. [Epub ahead of print]

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.Suda K1, Mizuuchi H2, Murakami I3, et al. Lung Cancer. 2014 Jun 2. pii: S0169-5002(14)00249-9. doi: 10.1016/j.lungcan.2014.05.018. [Epub ahead of print]

 

SCREENING, DIAGNOSIS AND STAGING

Impact of touch preparations on core needle biopsies.Tong LC1, Rudomina D, Rekhtman N, Lin O. Cancer Cytopathol. 2014 Jun 19. doi: 10.1002/cncy.21447. [Epub ahead of print]

Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma.Nakagiri T1, Sawabata N, Morii E, Inoue M, Shintani Y, Funaki S, Okumura M. Gen Thorac Cardiovasc Surg. 2014 Jun 3. [Epub ahead of print]

Combining COPD with Clinical, Pathological and Demographic Information Refines Prognosis and Treatment Response Prediction of Non-Small Cell Lung Cancer.Putila J, Guo NL. PLoS One. 2014 Jun 26;9(6):e100994. doi: 10.1371/journal.pone.0100994. eCollection 2014.

The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.Dormady S1, Broder MS, Putcha GV, et al. Int J Clin Oncol. 2014 Jun 6. [Epub ahead of print]

Time to smoke first morning cigarette and lung cancer in a case-control study.Gu F1, Wacholder S1, Kovalchik S1, et al. J Natl Cancer Inst. 2014 Jun 19;106(6):dju118. doi: 10.1093/jnci/dju118. Print 2014 Jun.

CT Screening for Lung Cancer: Alternative Definitions of Positive Test Result Based on the National Lung Screening Trial and International Early Lung Cancer Action Program Databases. Yip R1, Henschke CI, Yankelevitz DF, Smith JP. Radiology. 2014 Jun 19:132950. [Epub ahead of print]

Impact of lung cancer screening results on smoking cessation.Tammemägi MC1, Berg CD2, Riley TL2, Cunningham CR2, Taylor KL2. J Natl Cancer Inst. 2014 May 28;106(6):dju084. doi: 10.1093/jnci/dju084. Print 2014 Jun.

Panel based maldi-tof tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Sherwood JL1, Müller S2, Orr MC1, Ratcliffe MJ1, Walker J1. PLoS One. 2014 Jun 23;9(6):e100566. doi: 10.1371/journal.pone.0100566. eCollection 2014.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Usefulness of vessel-sealing devices for ≤7 mm diameter vessels: a randomized controlled trial for human thoracoscopic lobectomy in primary lung cancer.Toishi M1, Yoshida K2, Agatsuma H1, et al. Interact Cardiovasc Thorac Surg. 2014 Jun 3. pii: ivu176. [Epub ahead of print]

Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non-Small-Cell Lung Cancer.Fernando HC1, Landreneau RJ2, Mandrekar SJ2, et al. J Clin Oncol. 2014 Jun 30. pii: JCO.2013.53.4115. [Epub ahead of print]

Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non-Small-Cell Lung Cancer: A Propensity-Matched Analysis.Landreneau RJ1, Normolle DP2, Christie NA2, et al. J Clin Oncol. 2014 Jun 30. pii: JCO.2013.50.8762. [Epub ahead of print]

Outcome and prognostic factors of resected non-small cell lung cancer invading the diaphragm† Galetta D1, Borri A2, Casiraghi M2, et al. Interact Cardiovasc Thorac Surg. 2014 Jun 26. pii: ivu183. [Epub ahead of print]

The Influence of Body Mass Index and Weight Loss on Outcome of Elderly Patients Undergoing Lung Cancer Resection.Fiorelli A1, Vicidomini G1, Mazzella A1, et al. Thorac Cardiovasc Surg. 2014 Jun 24. [Epub ahead of print]

Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines.Yue D, Gong L, You J, Su Y, Zhang Z, Zhang Z, Gu F, Wang M, Wang C1. BMC Cancer. 2014 Jun 10;14(1):422. doi: 10.1186/1471-2407-14-422.

 

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial.Yang JC1, Kang JH2, Mok T3, et al. Eur J Cancer. 2014 Jun 18. pii: S0959-8049(14)00661-3. doi: 10.1016/j.ejca.2014.05.011. [Epub ahead of print]

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).Mok T1, Gorbunova V, Juhasz E, et al. J Thorac Oncol. 2014 Jun;9(6):848-55. doi: 10.1097/JTO.0000000000000160.

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.Gridelli C1, de Marinis F, Ardizzoni A, et al. J Cancer Res Clin Oncol. 2014 Jun 6. [Epub ahead of print]

Comparison of Efficacy and Safety between Liposome-paclitaxel Injection plus Carboplatin and Paclitaxel plus Carboplatin as First Line Treatment in Advanced Non-small Cell Lung Cancer. Hong-Yu W, Xiang-Ru Z. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Jun 28;36(3):305-8. doi: 10.3881/j.issn.1000-503X.2014.03.014.

The Effect of Radiotherapy Dose on Survival in Stage III Non-Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy.Koshy M1, Malik R2, Sher DJ3, et al. Clin Lung Cancer. 2014 Jun 2. pii: S1525-7304(14)00111-9. doi: 10.1016/j.cllc.2014.05.004. [Epub ahead of print]

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.Garon EB1, Ciuleanu TE2, Arrieta O3, et al. Lancet. 2014 Jun 2. pii: S0140-6736(14)60845-X. doi: 10.1016/S0140-6736(14)60845-X. [Epub ahead of print]

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Imai H1, Mori K, Ono A, et al. Med Oncol. 2014 Aug;31(8):88. doi: 10.1007/s12032-014-0088-3. Epub 2014 Jun 25.

Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. Song Z, Zhang Y. J Thorac Dis. 2014 Jun;6(6):856-60. doi: 10.3978/j.issn.2072-1439.2014.06.15.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity. Iguchi T1, Hiraki T, Gobara H, et al. Cardiovasc Intervent Radiol. 2014 Jun 18. [Epub ahead of print]

Role of Postoperative Radiotherapy After Curative Resection and Adjuvant Chemotherapy for Patients With Pathological Stage N2 Non-Small-Cell Lung Cancer: A Propensity Score Matching Analysis.Kim BH1, Kim HJ2, Wu HG1, Kang CH3, Kim YT3, Lee SH4, Kim DW4. Clin Lung Cancer. 2014 Jun 6. pii: S1525-7304(14)00112-0. doi: 10.1016/j.cllc.2014.05.005. [Epub ahead of print]

Assessment of interpatient heterogeneity in tumor radiosensitivity for nonsmall cell lung cancer using tumor-volume variation data.Chvetsov AV1, Yartsev S2, Schwartz JL1, Mayr N1. Med Phys. 2014 Jun;41(6):064101. doi: 10.1118/1.4875686.

The accuracy of the out-of-field dose calculations using a model based algorithm in a commercial treatment planning system.Wang L1, Ding GX. Phys Med Biol. 2014 Jul 7;59(13):N113-28. doi: 10.1088/0031-9155/59/13/N113. Epub 2014 Jun 13.

Quantification of gross tumour volume changes between simulation and first day of radiotherapy for patients with locally advanced malignancies of the lung and head/neck.Kishan AU1, Cui J, Wang PC, Daly ME, Purdy JA, Chen AM. J Med Imaging Radiat Oncol. 2014 Jun 18. doi: 10.1111/1754-9485.12196. [Epub ahead of print]

The impact of respiratory gating on lung dosimetry in stereotactic body radiotherapy for lung cancer.Jang SS1, Huh GJ2, Park SY3, Yang PS4, Cho EY5. Phys Med. 2014 Jun 2. pii: S1120-1797(14)00085-4. doi: 10.1016/j.ejmp.2014.05.005. [Epub ahead of print]

Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.Ouyang WW, Su SF, Ma Z, et al. Radiat Oncol. 2014 Jun 24;9(1):147. doi: 10.1186/1748-717X-9-147.

 

Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer.Wang Q1, Jiang Z, Qi X, Lu S, Wang S, Leng C, Lu F, Liu H, Liang S, Shi J. Clin Transl Oncol. 2014 Jun 4. [Epub ahead of print]

Radiation pneumonitis in patients with non–small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.Zhuang H1, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L,

Stereotactic body radiotherapy in patients with previous pneumonectomy: safety and efficacy. Thompson R1, Giuliani M, Yap ML, et al. J Thorac Oncol. 2014 Jun;9(6):843-7. doi: 10.1097/JTO.0000000000000159.

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis.Lara MS1, Brunson A2, Wun T2, Tomlinson B2, Qi L3, Cress R3, Gandara DR2, Kelly K4. Lung Cancer. 2014 May 6. pii: S0169-5002(14)00178-0. doi: 10.1016/j.lungcan.2014.04.007. [Epub ahead of print]

 

Immunotherapy for non-small-cell lung cancer.Thomas A1, Jakopovic M. Expert Opin Biol Ther. 2014 May 30:1-4. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials.Ardizzoni A1, Tiseo M2, Boni L3. Eur J Cancer. 2014 Jun 26. pii: S0959-8049(14)00742-4. doi: 10.1016/j.ejca.2014.06.002. [Epub ahead of print]

Tumor Cell Heterogeneity in Small Cell Lung Cancer (SCLC): Phenotypical and Functional Differences Associated with Epithelial-Mesenchymal Transition (EMT) and DNA Methylation Changes.Krohn A1, Ahrens T2, Yalcin A1, et al. PLoS One. 2014 Jun 24;9(6):e100249. doi: 10.1371/journal.pone.0100249. eCollection 2014.

The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Kang MH1, Go SI1, Song HN1, et al. Br J Cancer. 2014 Jun 12. doi: 10.1038/bjc.2014.317. [Epub ahead of print]

Small-cell lung cancers in patients who never smoked cigarettes. Varghese AM1, Zakowski MF, et al. J Thorac Oncol. 2014 Jun;9(6):892-6. doi: 10.1097/JTO.0000000000000142.

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.Ross JS1, Wang K2, Elkadi OR3, et al. J Clin Pathol. 2014 Jun 24. pii: jclinpath-2014-202447. doi: 10.1136/jclinpath-2014-202447. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

The creation of hope in patients with lung cancer.Salander P1, Bergknut M, Henriksson R. Acta Oncol. 2014 Jun 9:1-7. [Epub ahead of print]

Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer.Lee SJ1, Lee J, Park YS, Lee CH, Lee SM, Yim JJ, Yoo CG, Han SK, Kim YW. J Thorac Oncol. 2014 Jun;9(6):812-7. doi: 10.1097/JTO.0000000000000158.

Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. Strøm HH1, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U. J Thorac Oncol. 2014 Jun;9(6):825-33. doi: 10.1097/JTO.0000000000000184.

Home-based exercise: promising rehabilitation for symptom relief, improved functional status and quality of life for post-surgical lung cancer patients.Hoffman AJ, Brintnall RA, von Eye A, Jones LW, Alderink G, Patzelt LH, Brown JK. J Thorac Dis. 2014 Jun;6(6):632-40. doi: 10.3978/j.issn.2072-1439.2014.06.08.

Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system.Chubak J1, Aiello Bowles EJ, et al. J Cancer Surviv. 2014 Jun;8(2):229-38. doi: 10.1007/s11764-013-0335-1. Epub 2013 Dec 19.

Is the clinical use of cannabis by oncology patients advisable?Bar-Sela G, Avisar A, Batash R, Schaffer M1. Curr Med Chem. 2014 Jun;21(17):1923-30.

Lung cancer screening guidelines. The nurse’s role in patient education and advocacy.Lehto RH. Clin J Oncol Nurs. 2014 Jun;18(3):338-42. doi: 10.1188/14.CJON.338-342.

COMPLEMENTARY & ALTERNATIVE THERAPY

Antitumor effect of traditional Chinese herbal medicines against lung cancer.Chen Y1, Zhu J, Zhang W. Anticancer Drugs. 2014 Jun 2. [Epub ahead of print]

Phenolcarboxylic acids from medicinal herbs exert anticancer effects through disruption of COX-2 activity.Tao L1, Wang S1, Zhao Y1, Sheng X1, Wang A2, Zheng S2, Lu Y3. Phytomedicine. 2014 Jun 7. pii: S0944-7113(14)00222-0. doi: 10.1016/j.phymed.2014.05.001. [Epub ahead of print]

MISCELLANEOUS WORKS

Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium.Zhang LR1, Morgenstern H, Greenland S, et al. Int J Cancer. 2014 Jun 20. doi: 10.1002/ijc.29036. [Epub ahead of print]

Incidence of brain metastasis at initial presentation of lung cancer.Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Neuro Oncol. 2014 Jun 2. pii: nou099. [Epub ahead of print]

History of periodontal disease diagnosis and lung cancer incidence in the Women’s Health Initiative Observational Study.Mai X1, LaMonte MJ, Hovey KM, et al. Cancer Causes Control. 2014 Aug;25(8):1045-53. doi: 10.1007/s10552-014-0405-3. Epub 2014 Jun 10.

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Lu J1, Lee-Gabel L2, Nadeau MC2, Ferencz TM2, Soefje SA3. J Oncol Pharm Pract. 2014 Jun 9. pii: 1078155214538087. [Epub ahead of print]

Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.Gray PJ1, Mak RH2, Yeap BY3, et al. Lung Cancer. 2014 Jun 6. pii: S0169-5002(14)00256-6. doi: 10.1016/j.lungcan.2014.06.001. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)